Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Want to see HK:2197 full AI Analyst Report?
2197 Stock Chart & Stats
HK$2.37
>-HK$0.01(-2.10%)
At close: 4:00 PM EST
HK$2.37
>-HK$0.01(-2.10%)
Day’s Range― - ―
52-Week RangeHK$0.22 - HK$3.20
Previous CloseN/A
Volume1.38M
Average Volume (3M)29.82M
Market Cap
HK$3.32B
Enterprise ValueHK$2.67B
Total Cash (Recent Filing)HK$286.15M
Total Debt (Recent Filing)HK$10.62M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding1,298,233,800
10 Day Avg. Volume32,349,599
30 Day Avg. Volume29,824,166
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-1.47
Price to Sales (P/S)775.86
P/FCF Ratio-13.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Platform (Trimer‑Tag)Clover's proprietary trimer‑tag technology is a durable competitive asset that can be reused across vaccine candidates. A platform reduces per‑project discovery time, supports portfolio expansion and licensing, and underpins a long‑term R&D moat versus one‑off programs.
Integrated Vaccine CapabilitiesThe company's integrated R&D, manufacturing and commercialization capabilities lower reliance on external contractors. End‑to‑end control supports faster scale‑up, quality oversight and potential margin capture over time versus firms that must outsource core steps.
Modest Nominal Debt Burden ReportedDespite severe equity depletion, reported debt in 2025 is not large in absolute terms. Lower nominal debt reduces near‑term fixed financing obligations, giving management more runway to restructure operations or pursue financing for core programs.
Bears Say
Severe Revenue CollapseA ~93% revenue drop in 2025 is a structural red flag: it erodes scale, reduces bargaining power with partners, and undermines ability to support ongoing R&D and manufacturing. Sustained top‑line decline threatens the commercial viability of core programs.
Consistently Negative Shareholder EquityMulti‑year negative shareholder equity signals accumulated losses that constrain strategic flexibility. Negative equity complicates capital raises, increases lender/governance scrutiny, and heightens going‑concern and refinancing sensitivity for long‑term operations.
Persistent Cash Burn And Negative OCFConsistent negative operating and free cash flow across 2021–2025 indicates ongoing cash burn requiring external funding or asset reductions. This persistent cash deficit pressures R&D continuity, risks dilution, and increases the probability of program cuts.
Clover Biopharmaceuticals Ltd. News
2197 FAQ
What was Clover Biopharmaceuticals Ltd.’s price range in the past 12 months?
Clover Biopharmaceuticals Ltd. lowest stock price was HK$0.22 and its highest was HK$3.20 in the past 12 months.
What is Clover Biopharmaceuticals Ltd.’s market cap?
Clover Biopharmaceuticals Ltd.’s market cap is HK$3.32B.
When is Clover Biopharmaceuticals Ltd.’s upcoming earnings report date?
Clover Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 96 days.
How were Clover Biopharmaceuticals Ltd.’s earnings last quarter?
Clover Biopharmaceuticals Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.092.
Is Clover Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clover Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Clover Biopharmaceuticals Ltd. pay dividends?
Clover Biopharmaceuticals Ltd. does not currently pay dividends.
What is Clover Biopharmaceuticals Ltd.’s EPS estimate?
Clover Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Biopharmaceuticals Ltd. have?
Clover Biopharmaceuticals Ltd. has 1,298,233,800 shares outstanding.
What happened to Clover Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Clover Biopharmaceuticals Ltd. reported an EPS of -HK$0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.563%.
Which hedge fund is a major shareholder of Clover Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:2197
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
589.23%
12-Months-Change
Fundamentals
Return on Equity
11.40%
Trailing 12-Months
Asset Growth
-41.03%
Trailing 12-Months
Company Description
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Technical Analysis
Kintor Pharmaceutical Ltd
―
HBM Holdings Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---